These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28262569)

  • 1. Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection.
    Waters V; Yau Y; Beaudoin T; Wettlaufer J; Tom SK; McDonald N; Rizvi L; Klingel M; Ratjen F; Tullis E
    J Cyst Fibros; 2017 Jul; 16(4):492-495. PubMed ID: 28262569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two case reports of the successful eradication of new isolates of Burkholderia cepacia complex in children with cystic fibrosis.
    Kitt H; Lenney W; Gilchrist FJ
    BMC Pharmacol Toxicol; 2016 Mar; 17():14. PubMed ID: 27018049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
    Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
    Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination aerosol therapy to treat Burkholderia cepacia complex.
    Middleton PG; Kidd TJ; Williams B
    Eur Respir J; 2005 Aug; 26(2):305-8. PubMed ID: 16055880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
    Blumer JL; Saiman L; Konstan MW; Melnick D
    Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms.
    Kennedy S; Beaudoin T; Yau YC; Caraher E; Zlosnik JE; Speert DP; LiPuma JJ; Tullis E; Waters V
    Antimicrob Agents Chemother; 2016 Jan; 60(1):348-55. PubMed ID: 26503664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
    Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infection with Burkholderia cepacia complex bacteria and pulmonary exacerbations of cystic fibrosis.
    St Denis M; Ramotar K; Vandemheen K; Tullis E; Ferris W; Chan F; Lee C; Slinger R; Aaron SD
    Chest; 2007 Apr; 131(4):1188-96. PubMed ID: 17426227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can Burkholderia cepacia complex be eradicated with nebulised amiloride and TOBI?
    Ball R; Brownlee KG; Duff AJ; Denton M; Conway SP; Lee TW
    J Cyst Fibros; 2010 Jan; 9(1):73-4. PubMed ID: 19932062
    [No Abstract]   [Full Text] [Related]  

  • 12. An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa.
    Sutharsan S; Naehrig S; Mellies U; Sieder C; Ziegler J
    BMC Pulm Med; 2020 Jun; 20(1):167. PubMed ID: 32532226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
    Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
    Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients.
    Garcia BA; Carden JL; Goodwin DL; Smith TA; Gaggar A; Leon K; Antony VB; Rowe SM; Solomon GM
    BMC Pulm Med; 2018 Feb; 18(1):35. PubMed ID: 29444656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of initial colonisations with Burkholderia species in France, with retrospective analysis in five cystic fibrosis Centres: a pilot study.
    Gruzelle V; Guet-Revillet H; Segonds C; Bui S; Macey J; Chiron R; Michelet M; Murris-Espin M; Mittaine M
    BMC Pulm Med; 2020 Jun; 20(1):159. PubMed ID: 32503487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
    Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
    J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
    Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
    Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial.
    Galeva I; Konstan MW; Higgins M; Angyalosi G; Brockhaus F; Piggott S; Thomas K; Chuchalin AG
    Curr Med Res Opin; 2013 Aug; 29(8):947-56. PubMed ID: 23672633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
    Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
    J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.